French parliamentarians against cell-based meat
The French Republicans have tabled a bill in the National Assembly aimed at banning the commercialisation of cell-based meat in France.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2213 entries already.
Entries by Thomas Gabrielczyk
Vandria SA bags CHF18m in Series A financing
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.
Cell-free protein synthesis systems
Cell-free protein synthesis (CFPS) systems allow rapid protein production in vitro without the need for living cells, offering distinct advantages.
Antabio SAS raises €25 m in Series B financing
Antibiotics specialist Antabio SAS has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from existing investors.
Production process for cell-based coffee published
Scientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.
Germany blocks deregulation of NGT breeds
At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the adapted version of the EU Commission’s draft regulation on new genomic techniques.
Cathera SA closes Series B round at €42m
Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.
UK publishes £2bn vision for engineering biology
On the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Valnevas Lyme vaccine trial completes recruitment
Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Takeover in ADC space: Abbvie snags ImmunoGen
AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.